Screening for asymptomatic conditions is an essential and important aspect of primary care. But what is the potential downstream impact to the patents and the healthcare system when low-risk individuals are screened? What are the benefits and the potential harms? Join us as we discuss a recent retrospective study on the downstream effects of low-value testing on low-risk people at their annual health exam and how this may impact your practice.